INMUNE BIO INC. APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition
INMUNE BIO INC. (INMB) reported APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition of $1.36 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition · last filed 2026-08-06
- INMUNE BIO INC. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2026-06-30 was $1.36M, a 11.47% decline year-over-year.
- INMUNE BIO INC. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2026-03-31 was $1.50M, a 27.89% decline year-over-year.
- INMUNE BIO INC. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2025-09-30 was $2.98M, a 73.59% increase year-over-year.
- INMUNE BIO INC. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2025-06-30 was $1.53M, a 34.72% decline year-over-year.
- INMUNE BIO INC. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2025 was $9.91M, a 30.31% increase from fiscal 2024.
- INMUNE BIO INC. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2024 was $7.61M, a 3.22% increase from fiscal 2023.
- INMUNE BIO INC. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2023 was $7.37M, a 3.06% increase from fiscal 2022.
- INMUNE BIO INC. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2022 was $7.15M.
| Period end | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 3 month as first filed | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $1.36M 10-Q · filed 2026-08-06 | $2.85M derived: sum of 2 quarters · filed 2026-08-06 | |||
| 2026-03-31 | $1.50M 10-Q · filed 2026-08-06 | ||||
| 2025-12-31 | $9.91M 10-K · filed 2026-03-30 | ||||
| 2025-09-30 | $2.98M 10-Q · filed 2025-10-30 | $4.52M derived: sum of 2 quarters · filed 2026-08-06 | $6.59M derived: sum of 3 quarters · filed 2026-08-06 | ||
| 2025-06-30 | $1.53M 10-Q · filed 2026-08-06 | $3.61M derived: sum of 2 quarters · filed 2026-08-06 | |||
| 2025-03-31 | $2.08M 10-Q · filed 2026-08-06 | ||||
| 2024-12-31 | $7.61M 10-K · filed 2026-03-30 | ||||
| 2024-09-30 | $1.72M 10-Q · filed 2025-10-30 | $4.07M derived: sum of 2 quarters · filed 2025-10-30 | $5.85M derived: sum of 3 quarters · filed 2025-10-30 | $7.73M derived: sum of 4 quarters · filed 2025-10-30 | |
| 2024-06-30 | $2.35M 10-Q · filed 2025-10-30 | $4.13M derived: sum of 2 quarters · filed 2025-10-30 | $6.01M derived: sum of 3 quarters · filed 2025-10-30 | $7.90M derived: sum of 4 quarters · filed 2025-10-30 | |
| 2024-03-31 | $1.78M 10-Q · filed 2025-10-30 | $3.66M derived: sum of 2 quarters · filed 2025-10-30 | $5.55M derived: sum of 3 quarters · filed 2025-10-30 | $7.41M derived: sum of 4 quarters · filed 2025-10-30 | |
| 2023-12-31 | $1.88M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $3.77M derived: sum of 2 quarters · filed 2025-03-27 | $5.63M derived: sum of 3 quarters · filed 2025-03-27 | $7.37M 10-K · filed 2025-03-27 | |
| 2023-09-30 | $1.89M 10-Q · filed 2024-10-31 | $3.75M derived: sum of 2 quarters · filed 2024-10-31 | $5.49M 10-Q · filed 2023-11-01 | $7.28M derived: sum of 4 quarters · filed 2024-10-31 | |
| 2023-06-30 | $1.86M 10-Q · filed 2024-10-31 | $3.60M 10-Q · filed 2023-08-07 | $5.39M derived: sum of 3 quarters · filed 2024-10-31 | $7.33M derived: sum of 4 quarters · filed 2024-10-31 | |
| 2023-03-31 | $1.74M 10-Q · filed 2024-10-31 | $1.86M 10-Q · filed 2023-08-07 | $3.52M derived: sum of 2 quarters · filed 2024-10-31 | $5.46M derived: sum of 3 quarters · filed 2024-10-31 | $7.00M derived: sum of 4 quarters · filed 2024-10-31 |
| 2022-12-31 | $1.79M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $3.73M derived: sum of 2 quarters · filed 2024-03-28 | $5.26M derived: sum of 3 quarters · filed 2024-03-28 | $7.15M 10-K · filed 2024-03-28 | |
| 2022-09-30 | $1.94M 10-Q · filed 2023-11-01 | $3.48M derived: sum of 2 quarters · filed 2023-11-01 | $5.36M 10-Q · filed 2023-11-01 | ||
| 2022-06-30 | $1.54M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $3.42M 10-Q · filed 2023-08-07 | |||
| 2022-03-31 | $1.89M 10-Q · filed 2023-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B |